tiprankstipranks
Biomarin Pharmaceutical Inc. (BMRN)
NASDAQ:BMRN
US Market
BMRN
BioMarin Pharmaceutical
RESEARCH TOOLSreports
Want to see BMRN full AI Analyst Report?

BioMarin Pharmaceutical (BMRN) Stock Forecast & Price Target

2,443 Followers
See the Price Targets and Ratings of:

BMRN Analyst Ratings

Moderate Buy
18Ratings
Moderate Buy
13 Buy
5 Hold
0 Sell
Based on 18 analysts giving stock ratings to
BioMarin
Pharmaceutical
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BMRN Stock 12 Month Forecast

Average Price Target

$85.88
▲(44.75% Upside)
Based on 18 Wall Street analysts offering 12 month price targets for BioMarin Pharmaceutical in the last 3 months. The average price target is $85.88 with a high forecast of $120.00 and a low forecast of $60.00. The average price target represents a 44.75% change from the last price of $59.33.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"52":"$52","121":"$121","69.25":"$69.3","86.5":"$86.5","103.75":"$103.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":120,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$120.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":85.88235294117646,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$85.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$60.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[52,69.25,86.5,103.75,121],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,60.02,64.63384615384615,69.2476923076923,73.86153846153846,78.47538461538461,83.08923076923077,87.70307692307692,92.31692307692308,96.93076923076923,101.54461538461538,106.15846153846154,110.77230769230769,115.38615384615383,{"y":120,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,60.02,62.00941176470589,63.998823529411766,65.98823529411764,67.97764705882354,69.96705882352941,71.95647058823529,73.94588235294117,75.93529411764706,77.92470588235294,79.91411764705882,81.90352941176471,83.89294117647059,{"y":85.88235294117646,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,60.02,60.018461538461544,60.01692307692308,60.01538461538462,60.01384615384615,60.012307692307694,60.010769230769235,60.00923076923077,60.00769230769231,60.00615384615385,60.004615384615384,60.003076923076925,60.00153846153846,{"y":60,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":58.14,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.09,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.86,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.57,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.03,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.43,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.95,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.74,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.24,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.06,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.03,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.82,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.02,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$120.00Average Price Target$85.88Lowest Price Target$60.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on BMRN
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$50→$60
Hold
1.13%
Upside
Reiterated
08/07/26
BioMarin price target raised to $60 from $50 at H.C. WainwrightBioMarin price target raised to $60 from $50 at H.C. Wainwright
Bank of America Securities Analyst forecast on BMRN
Jason Gerberry
Bank of America Securities
Bank of America Securities
$80→$86
Buy
44.95%
Upside
Reiterated
08/06/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Genmab (NASDAQ: GMAB), Cytokinetics (NASDAQ: CYTK) and BioMarin Pharmaceutical (NASDAQ: BMRN)
Barclays Analyst forecast on BMRN
Eliana Merle
Barclays
Barclays
$105
Buy
76.98%
Upside
Reiterated
07/23/26
BioMarin Pharmaceutical (BMRN) Gets a Buy from Barclays
Citi Analyst forecast on BMRN
Eric Joseph
Citi
Citi
$75→$76
Buy
28.10%
Upside
Reiterated
07/16/26
BioMarin price target raised to $76 from $75 at CitiBioMarin price target raised to $76 from $75 at Citi
RBC Capital Analyst forecast on BMRN
Luca Issi
RBC Capital
RBC Capital
$66→$62
Hold
4.50%
Upside
Reiterated
07/07/26
BioMarin price target lowered to $62 from $66 at RBC CapitalBioMarin price target lowered to $62 from $66 at RBC Capital
Jefferies Analyst forecast on BMRN
Akash Tewari
Jefferies
Jefferies
$104
Buy
75.29%
Upside
Reiterated
07/06/26
Jefferies Sticks to Its Buy Rating for BioMarin Pharmaceutical (BMRN)
Guggenheim Analyst forecast on BMRN
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
$86
Buy
44.95%
Upside
Reiterated
06/03/26
BioMarin Pharmaceutical (BMRN) Receives a Buy from Guggenheim
Stifel Nicolaus Analyst forecast on BMRN
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$68
Hold
14.61%
Upside
Reiterated
05/24/26
BioMarin Pharmaceutical (BMRN) Receives a Hold from Stifel Nicolaus
Canaccord Genuity Analyst forecast on BMRN
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$116→$111
Buy
87.09%
Upside
Reiterated
05/22/26
BioMarin price target lowered to $111 from $116 at CanaccordBioMarin price target lowered to $111 from $116 at Canaccord
Raymond James Analyst forecast on BMRN
Christopher Raymond
Raymond James
Raymond James
―
Buy
―
Reiterated
05/22/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Piper Sandler Analyst forecast on BMRN
Allison Bratzel
Piper Sandler
Piper Sandler
$84→$82
Buy
38.21%
Upside
Reiterated
05/21/26
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN) and Roivant Sciences (NASDAQ: ROIV)
Evercore ISI Analyst forecast on BMRN
Cory Kasimov
Evercore ISI
Evercore ISI
$120
Buy
102.26%
Upside
Reiterated
05/21/26
Analysts Offer Insights on Healthcare Companies: Vaxcyte (NASDAQ: PCVX) and BioMarin Pharmaceutical (NASDAQ: BMRN)
Wells Fargo Analyst forecast on BMRN
Mohit Bansal
Wells Fargo
Wells Fargo
$75
Buy
26.41%
Upside
Assigned
05/21/26
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT) and BioMarin Pharmaceutical (NASDAQ: BMRN)
TD Cowen Analyst forecast on BMRN
Phil Nadeau
TD Cowen
TD Cowen
$120
Buy
102.26%
Upside
Reiterated
05/21/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wedbush Analyst forecast on BMRN
Yun Zhong
Wedbush
Wedbush
$94
Buy
58.44%
Upside
Assigned
05/21/26
Buy Rating Reaffirmed on BioMarin as Voxzogo Skeletal Disorder Opportunity Expands; $94 Price Target Maintained
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on BMRN
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$50→$60
Hold
1.13%
Upside
Reiterated
08/07/26
BioMarin price target raised to $60 from $50 at H.C. WainwrightBioMarin price target raised to $60 from $50 at H.C. Wainwright
Bank of America Securities Analyst forecast on BMRN
Jason Gerberry
Bank of America Securities
Bank of America Securities
$80→$86
Buy
44.95%
Upside
Reiterated
08/06/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Genmab (NASDAQ: GMAB), Cytokinetics (NASDAQ: CYTK) and BioMarin Pharmaceutical (NASDAQ: BMRN)
Barclays Analyst forecast on BMRN
Eliana Merle
Barclays
Barclays
$105
Buy
76.98%
Upside
Reiterated
07/23/26
BioMarin Pharmaceutical (BMRN) Gets a Buy from Barclays
Citi Analyst forecast on BMRN
Eric Joseph
Citi
Citi
$75→$76
Buy
28.10%
Upside
Reiterated
07/16/26
BioMarin price target raised to $76 from $75 at CitiBioMarin price target raised to $76 from $75 at Citi
RBC Capital Analyst forecast on BMRN
Luca Issi
RBC Capital
RBC Capital
$66→$62
Hold
4.50%
Upside
Reiterated
07/07/26
BioMarin price target lowered to $62 from $66 at RBC CapitalBioMarin price target lowered to $62 from $66 at RBC Capital
Jefferies Analyst forecast on BMRN
Akash Tewari
Jefferies
Jefferies
$104
Buy
75.29%
Upside
Reiterated
07/06/26
Jefferies Sticks to Its Buy Rating for BioMarin Pharmaceutical (BMRN)
Guggenheim Analyst forecast on BMRN
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
$86
Buy
44.95%
Upside
Reiterated
06/03/26
BioMarin Pharmaceutical (BMRN) Receives a Buy from Guggenheim
Stifel Nicolaus Analyst forecast on BMRN
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$68
Hold
14.61%
Upside
Reiterated
05/24/26
BioMarin Pharmaceutical (BMRN) Receives a Hold from Stifel Nicolaus
Canaccord Genuity Analyst forecast on BMRN
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$116→$111
Buy
87.09%
Upside
Reiterated
05/22/26
BioMarin price target lowered to $111 from $116 at CanaccordBioMarin price target lowered to $111 from $116 at Canaccord
Raymond James Analyst forecast on BMRN
Christopher Raymond
Raymond James
Raymond James
―
Buy
―
Reiterated
05/22/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Piper Sandler Analyst forecast on BMRN
Allison Bratzel
Piper Sandler
Piper Sandler
$84→$82
Buy
38.21%
Upside
Reiterated
05/21/26
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN) and Roivant Sciences (NASDAQ: ROIV)
Evercore ISI Analyst forecast on BMRN
Cory Kasimov
Evercore ISI
Evercore ISI
$120
Buy
102.26%
Upside
Reiterated
05/21/26
Analysts Offer Insights on Healthcare Companies: Vaxcyte (NASDAQ: PCVX) and BioMarin Pharmaceutical (NASDAQ: BMRN)
Wells Fargo Analyst forecast on BMRN
Mohit Bansal
Wells Fargo
Wells Fargo
$75
Buy
26.41%
Upside
Assigned
05/21/26
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT) and BioMarin Pharmaceutical (NASDAQ: BMRN)
TD Cowen Analyst forecast on BMRN
Phil Nadeau
TD Cowen
TD Cowen
$120
Buy
102.26%
Upside
Reiterated
05/21/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wedbush Analyst forecast on BMRN
Yun Zhong
Wedbush
Wedbush
$94
Buy
58.44%
Upside
Assigned
05/21/26
Buy Rating Reaffirmed on BioMarin as Voxzogo Skeletal Disorder Opportunity Expands; $94 Price Target Maintained
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
TNYATenaya Therapeutics
JBIOJade Biosciences
GHRSGH Research
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BioMarin Pharmaceutical

3 Months
Akash TewariJefferies
Success Rate
13/31 ratings generated profit
42%
Average Return
-2.38%
Copying Akash Tewari's trades and holding each position for 3 Months would result in 41.94% of your transactions generating a profit, with an average return of -2.38% per trade.
1 Year
Cory KasimovEvercore ISI
Success Rate
20/42 ratings generated profit
48%
Average Return
-3.30%
Copying Cory Kasimov's trades and holding each position for 1 Year would result in 47.62% of your transactions generating a profit, with an average return of -3.30% per trade.
2 Years
William PickeringBernstein
Success Rate
7/13 ratings generated profit
54%
Average Return
+0.04%
Copying William Pickering's trades and holding each position for 2 Years would result in 53.85% of your transactions generating a profit, with an average return of +0.04% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BMRN Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
13
27
26
25
3
Buy
13
11
6
7
2
Hold
6
10
10
13
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
32
48
42
45
11
In the current month, BMRN has received 5 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. BMRN average Analyst price target in the past 3 months is 85.88.
Each month's total comprises the sum of three months' worth of ratings.

BMRN Financial Forecast

BMRN Earnings Forecast

Next quarter’s earnings estimate for BMRN is $1.46 with a range of $1.22 to $1.71. The previous quarter’s EPS was $1.20. BMRN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 45.99% of the time in the same period. In the last calendar year BMRN has Performed in-line its overall industry.
Next quarter’s earnings estimate for BMRN is $1.46 with a range of $1.22 to $1.71. The previous quarter’s EPS was $1.20. BMRN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 45.99% of the time in the same period. In the last calendar year BMRN has Performed in-line its overall industry.

BMRN Sales Forecast

Next quarter’s sales forecast for BMRN is $1.04B with a range of $991.50M to $1.08B. The previous quarter’s sales results were $989.71M. BMRN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 30.22% of the time in the same period. In the last calendar year BMRN has Performed in-line its overall industry.
Next quarter’s sales forecast for BMRN is $1.04B with a range of $991.50M to $1.08B. The previous quarter’s sales results were $989.71M. BMRN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 30.22% of the time in the same period. In the last calendar year BMRN has Performed in-line its overall industry.

BMRN Stock Forecast FAQ

What is BMRN’s average 12-month price target, according to analysts?
Based on analyst ratings, Biomarin Pharmaceutical Inc.’s 12-month average price target is 85.88.
    What is BMRN’s upside potential, based on the analysts’ average price target?
    Biomarin Pharmaceutical Inc. has 44.75% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BMRN a Buy, Sell or Hold?
          Biomarin Pharmaceutical Inc. has a consensus rating of Moderate Buy which is based on 13 buy ratings, 5 hold ratings and 0 sell ratings.
            What is Biomarin Pharmaceutical Inc.’s price target?
            The average price target for Biomarin Pharmaceutical Inc. is 85.88. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $120.00 ,the lowest forecast is $60.00. The average price target represents 44.75% Increase from the current price of $59.33.
              What do analysts say about Biomarin Pharmaceutical Inc.?
              Biomarin Pharmaceutical Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 18 Wall Streets Analysts.
                How can I buy shares of BMRN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.